Search Results 551-560 of 17580 for Toxin

  1. A Study of Copanlisib and Nivolumab in Treating Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma - Mayo Clinic

    Patients who have had chemotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C), anticancer antibodies within 4 weeks, radio or toxin ...

  2. Estrogen Receptor Positive Breast Cancer Clinical Trials - Mayo Clinic Research

    In traditional Chinese medicine, it is used for enhancing function and removing toxins, as well as for cancer, hepatitis, and infections. There is previous ...

  3. https://www.mayoclinic.org/chinese_patient_consumer_video.xml

  4. I-124 evuzamitide PET/CT Imaging for the Diagnosis of Cardiac Amyloidosis - Mayo Clinic

    Inclusion Criteria: Understands the study procedures and can give signed informed consent (as specified in Section 10.1.3), which includes compliance with ...

  5. Untitled

    Page 1.

  6. A Study To Evaluate Efficacy And Safety Of Tulisokibart (MK-7240) In Participants With Moderately To Severely Active Ulcerative Colitis (MK-7240-001) - Mayo Clinic

    Stool positive for pathogens (eg, Clostridioides difficile toxin, pathogenic Escherichia coli, Salmonella species, Shigella species, Campylobacter species, ...

  7. Mayo Clinic Transplant Center - Doctors

    Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, Florida and Minnesota.

  8. Gastroenterology and Hepatology - Clinical trials

    [MUSIC PLAYING]. Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first.

  9. Myocardial Ischemia and Transfusion - Mayo Clinic

    Inclusion Criteria: 18 years of age or older; Either ST segment elevation myocardial infarction or Non ST segment elevation myocardial infarction consistent ...

  10. Induction Therapy With RO7790121 in Patients With Moderately To Severely Active Ulcerative Colitis - Mayo Clinic

    difficile toxin testing) within 60 days prior to randomization (Day 1) or other enteric pathogens (as assessed by stool culture and ova and parasite ...